View Letter to the Duchenne Community As recently as March 9, CureDuchenne was helping NS Pharma get the word out about their newly launched Expanded Access Program for enabling access to viltolarsen, a treatment for patients with DMD amenable to exon 53 skipping, while the FDA reviews the therapy. How much has changed in two […]
THE CURRENT ADVICE FROM THE PROFESSIONAL SOCIETIES IS TO CONTINUE WITH ACE-I AND ARBS. The European Society of Cardiology (ESC) Council on Hypertension announced their stance in a positioning statement on March 13, and the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) published a joint statement […]
As a mom, a family, a friend, an advocate and a community, we know that the spread of the coronavirus disease 2019 (COVID-19) is clearly creating challenging times that call for the entire Duchenne community to come together and support each other. Through these challenging times, I wanted to personally assure you that CureDuchenne is […]
If you or your child is covered by Medicare – Starting on March 6th, Medicare has broadened coverage for telehealth services so that you may be able to access your physician and other providers by phone rather than having to risk traveling to a healthcare facility. It covers telehealth visits with doctors, nurse practitioners, clinical […]
What you can do, Cares Events, Updates and More With the coronavirus (COVID-19) situation evolving, CureDuchenne is closely monitoring the latest developments using the World Health Organization, Centers for Disease Control, local health authorities and close healthcare partners as sources of up-to-date information.  In light of this, we’re writing to highlight a few important areas […]
NEWPORT BEACH, Calif., (March 10, 2020) – CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their advancement to Phase III Clinical Trial for PF-06939926. The webinar will take place on Wednesday, March 11:00am PT/2:00pm ET and features Dr. Beth Belluscio, Pfizer Global Clinical […]
3/13/2020: UPDATED ANNOUNCEMENT AVAILABLE HERE » We never want to put anyone from the Duchenne community at risk, and with the statements from the CDC regarding travel risks, especially for persons with compromised immune systems, we want to let everyone know that we will be changing the format and dates of some of our upcoming in-person […]
CureDuchenne congratulates Pfizer on their progress to a Phase III clinical trial for #PF-06939926, its AAV9 mini-dystrophin gene therapy for Duchenne muscular dystrophy. We’re grateful to Pfizer for their dedication to the Duchenne community. Pfizer’s announcement is a big step forward for gene therapy efforts in Duchenne, an innovative field where there is still so […]

Thank You For A Great Year!

CureDuchenne has wrapped up our 2019 Webinar Series. We are committed to delivering the most up-to-date and accurate information to the Duchenne Community and are honored to have had the opportunity to collaborate with such well respected and forward thinking partners. If you missed any of this year’s webinars or want to revisit, they have […]

CureDuchenne Biobank

AUTHOR: Romina Foster-Bonds (View Spanish Version Below) CureDuchenne has made a significant commitment to develop and maintain a biobank dedicated to Duchenne muscular dystrophy — the CureDuchenne Biobank. The CureDuchenne Biobank will help clinicians and researchers spend their time doing what they do best — investigating important research questions. CureDuchenne is intimately connected to the […]
1 2 3 28